P3H1 promotes malignant progression of esophageal squamous cell carcinoma (ESCC) and modulates the immune microenvironment.

ABSTRACT:

Background

Esophageal squamous cell carcinoma (ESCC) is the predominant subtype of esophageal cancer (EC) in China and carries high lethality, in part because early disease is typically asymptomatic and thus diagnosed at advanced stages. To address the need for new biomarkers and targets, we investigated prolyl 3‑hydroxylase 1 (P3H1), a collagen‑modifying enzyme with emerging roles in cancer, aiming to clarify its contribution to ESCC progression and its potential as a prognostic biomarker and therapeutic target.

Methods

We integrated clinical and transcriptional profiles of ESCC from public datasets [The Cancer Genome Atlas (TCGA); Gene Expression Omnibus (GEO) cohorts GSE53623 and GSE53624] and single‑cell RNA‑seq data (GSE154763) to evaluate P3H1 expression, clinicopathol

SUBMITTER: Gu Y 

PROVIDER: S-EPMC12603417 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature